These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38819948)

  • 1. Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients.
    Ceccarelli F; Picciariello L; Natalucci F; Moretti V; Spinelli FR; Alessandri C; Conti F
    Clin Exp Rheumatol; 2024 May; ():. PubMed ID: 38819948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health-Related Quality of Life.
    Lai NS; Lu MC; Chang HH; Lo HC; Hsu CW; Huang KY; Tung CH; Hsu BB; Wu CH; Koo M
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34063379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.
    Jesus D; Matos A; Henriques C; Zen M; Larosa M; Iaccarino L; Da Silva JAP; Doria A; Inês LS
    Ann Rheum Dis; 2019 Mar; 78(3):365-371. PubMed ID: 30626657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of disease activity with depression and anxiety in systemic lupus erythematosus: A comparison of SLEDAI-2K and SLE-DAS.
    Yang L; Gu B; Wang X; Ren Q; Shen M; Su D
    Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38305645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.
    Chitpet P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P; Leosuthamas P; Pakchotanon R
    Int J Rheum Dis; 2023 Dec; 26(12):2509-2516. PubMed ID: 37875327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of SLE-DAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes.
    Onishi A; Tsuji H; Takase Y; Nakakubo Y; Iwasaki T; Kozuki T; Yoshida T; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Yoshifuji H; Tanaka M; Morinobu A
    Rheumatology (Oxford); 2023 Dec; 62(12):3909-3915. PubMed ID: 36943365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
    Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
    Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
    Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
    Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
    Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.
    Saraiva L; Cunha RN; Jesus D; Gatto M; Zen M; Iaccarino L; da Silva JAP; Doria A; Inês LS
    Rheumatology (Oxford); 2024 Apr; 63(4):1123-1129. PubMed ID: 37458482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness of Belimumab in Patients with Active Lupus.
    Sumichika Y; Yoshida S; Suzuki E; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of hospital admissions in patients with active systemic lupus erythematosus (SLE) classified according to two different SLE disease activity indices: a prospective cohort study.
    Lu MC; Hsu CW; Koo M; Lai NS
    Clin Exp Rheumatol; 2023 Jul; 41(7):1409-1416. PubMed ID: 36377575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study.
    Hunnicutt JN; Fairburn-Beech J; Georgiou ME; Richards A; Gregan YI; Quasny H; Chauhan D
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36450407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients.
    Jesus D; Rodrigues M; Matos A; Henriques C; Pereira da Silva JA; Inês LS
    Lupus; 2019 Apr; 28(5):607-612. PubMed ID: 30895904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased frequency of hospital admissions with active systemic lupus erythematosus disease activity defined by two different disease activity indices: A cohort study.
    Wang CL; Koo M; Hsu CW; Lu MC
    Lupus; 2023 Jun; 32(7):864-872. PubMed ID: 37165549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Lupus; 2021 Sep; 30(10):1586-1595. PubMed ID: 34192957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS.
    Koo M; Lu MC
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.